Radical multimodality therapy for malignant pleural mesothelioma
References
Additional references
Abdel‐Rahman O, Kelany M. Systemic therapy options for malignant pleural mesothelioma beyond first‐line therapy: a systematic review. Expert Review of Respiratory Medicine 2015;9(5):533‐49.
Abdel‐Rahman O. Role of postoperative radiotherapy in the management of malignant pleural mesothelioma: A propensity score matching of the SEER database. Strahlentherapie und Onkologie 2017 Jan 2 [Epub ahead of print]. [DOI: 10.1007/s00066‐016‐1092‐7]
Algranti E, Saito CA, Carneiro AP, Moreira B, Mendonca EM, Bussacos MA. The next mesothelioma wave: mortality trends and forecast to 2030 in Brazil. Cancer Epidemiology 2015;39(5):687‐92.
Allen A M, Czerminska M, Janne P A, Sugarbaker D J, Bueno R, Harris J R, et al. Fatal pneumonitis associated with intensity‐modulated radiation therapy for mesothelioma. International Journal of Radiation, Oncology, Biology and Physics 2006;65(3):640‐5.
Armato SG, Labby ZE, Coolen J, Klabatsa A, Feigen M, Persigehl T, et al. Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group. Lung Cancer 2013;82(2):190‐6.
Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S. ESMO Guidelines Committee. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Annals of Oncology 2015;26(Suppl 5):v31‐9.
Bertoglio P, Waller DA. The role of thoracic surgery in the management of mesothelioma: an expert opinion on the limited evidence. Expert Review of Respiratory Medicine 2016;10(6):663‐72.
Bianchi C, Bianchi T. Malignant mesothelioma: global incidence and relationship with asbestos. Industrial Health 2007;45(3):379‐87.
Bridda A, Padoan I, Mencarelli R, Frego M. Peritoneal mesothelioma: a review. Medscape General Medicine 2007;9(2):32.
Brčić L, Jakopović M, Brčić I, Klarić V, Milošević M, Sepac A, et al. Reproducibility of histological subtyping of malignant pleural mesothelioma. Virchows Archives 2014;465(6):679‐85.
Calabro L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, et al. Tremelimumab for patients with chemotherapy‐resistant advanced malignant mesothelioma: an open‐label, single‐arm, phase 2 trial. Lancet Oncology 2013;14(11):1104‐11.
Calabro L, Morra A, Fonsatti E, Cutaia O, Fazio C, Annesi D, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy‐resistant malignant mesothelioma: an open‐label, single‐arm, phase 2 study. Lancet Respiratory Medicine 2015;3(4):301‐9.
Chapman E, García Diéguez M. Radiotherapy for malignant pleural mesothelioma. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD003880.pub4]
US Department of Health and Human Services. Common terminology criteria of adverse events (CTCAE). Version 4.03. evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010‐06‐14_QuickReference_5x7.pdf Accessed prior to 27 February 2017.
De Perrot M, Feld R, Leighl NB, Hope A, Waddell TK, Keshavjee S, et al. Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma. Journal of Thoracic and Cardiovascular Surgery 2016;151(2):468‐73.
Egger M, Smith GD, Phillips AN. Meta‐analysis: principles and procedures. British Medical Journal 1997;315(7121):1533‐7.
Friedberg JS. Photodynamic therapy for malignant pleural mesothelioma. Journal of the National Cancer Institute 2012;10(Suppl 2):S75‐9.
Friedberg JS, Simone CB, Culligan MJ, Barsky AR, Doucette A, McNulty S, et al. Extended pleurectomy‐decortication–based treatment for advanced stage epithelial mesothelioma yielding a median survival of nearly three years. Annals of Thoracic Surgery 2017;103(3):912‐9.
Galateau‐Salle F, Churg A, Roggli V, Travis WD. World Health Organization Committee for Tumors of the Pleura. The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 classification. Journal of Thoracic Oncology 2016;11(2):142‐54.
GRADE Working Group, McMaster University. GRADEpro GDT. Version Accessed prior to 27 February 2017. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
Heelan RT, Rusch VW, Begg CB, Panicek DM, Caravelli JF, Eisen C. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. American Journal of Roentgenology 1999;172(4):1039‐47.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21(11):1539‐58.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011.Available from www.cochrane‐handbook.org, [updated March 2011].
Kadota K, Suzuki K, Sima CS, Rusch VW, Adusumilli PS, Travis WD. Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma. Journal of Thoracic Oncology 2011;6(5):896‐904.
Macaskill P, Walter S D, Irwig L. A comparison of methods to detect publication bias in meta‐analysis. Statistics in Medicine 2001;20:641‐54.
Macleod N, Price A, O'Rourke N, Fallon M, Laird B. Radiotherapy for the treatment of pain in malignant pleural mesothelioma: a systematic review. Lung Cancer 2014;83(2):133‐8.
MacLeod N, Chalmers A, O'Rourke N, Moore K, Sheridan J, McMahon L, et al. Is radiotherapy useful for treating pain in mesothelioma?: A phase II trial. Journal of Thoracic Oncology 2015;10(6):944‐50.
Manegold C. Pemetrexed (Alimta, MTA, multitargeted antifolate, LY231514) for malignant pleural mesothelioma. Seminars in Oncology 2003;30(4 Suppl 10):32‐6.
Mohamed H, Eltobgy M, Abdel‐Rahman O. Immune checkpoints aberrations and malignant mesothelioma: Assessment of prognostic value and evaluation of therapeutic potentials. Anticancer Agents in Medicinal Chemistry 2017 Jan 2 [Epub ahead of print].
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Med 2009;6(7):e1000097.
Pruefer FG, Lizarraga F, Maldonado V, Melendez‐Zajgla J. Participation of Omi Htra2 serine‐protease activity in the apoptosis induced by cisplatin on SW480 colon cancer cells. Journal of Chemotherapy 2008;20(3):348‐54.
Copenhagen: The Nordic Cochrane Centre,The Cochrane Collaboration. Review Manager (RevMan).Version 5.3. Copenhagen: The Nordic Cochrane Centre,The Cochrane Collaboration, 2014.
Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Annals of Cardiothoracic Surgery2012; Vol. 1, issue 4:491‐6.
Runxiao L, Yankun C, Lan W. A pilot study of volumetric‐modulated arc therapy for malignant pleural mesothelioma. Journal of Applied Clinical Medical Physics 2016;17(2):5980.
Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, Harrison L, et al. A phase II trial of surgical resection and adjuvant high‐dose hemithoracic radiation for malignant pleural mesothelioma. Journal of Thoracic and Cardiovascular surgery2001; Vol. 122, issue 4:788‐95.
Rusch VW, Chansky K, Kindler HL, Nowak AK, Pass HI, Rice DC, et al. The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. Journal of Thoracic Oncology 2016;11(12):2112‐9.
Saini R, Lee NV, Liu KY, Poh CF. Prospects in the application of photodynamic therapy in oral cancer and premalignant lesions. Cancers 2016;8(9):83‐6.
Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. European Respiratory Journal 2010;35(3):479‐95.
Stahel RA, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, et al. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncology 2015;16(16):1651‐8.
Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long‐term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. Journal of Thoracic and Cardiovascular Surgery 1999;117(1):54‐63; 63‐5.
Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nature Genetics 2011;43(10):1022‐5.
Treasure T, Lang‐Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, et al. MARS Trialists. Extra‐pleural pneumonectomy versus no extra‐pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncology 2011;12(8):763‐72.
Van Meerbeeck JP, Scherpereel A, Surmont VF, Baas P. Malignant pleural mesothelioma: the standard of care and challenges for future management. Critical reviews in Hematology/Oncology2011; Vol. 78, issue 2:92‐111.
Van Schil PE, Baas P, Gaafar R, Maat AP, Van de Pol M, Hasan B, et al. European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. European Respiratory Journal2010; Vol. 36, issue 6:1362‐9.
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of Clinical Oncology 2003;21(14):2636‐44.
Weder W, Opitz I. Multimodality therapy for malignant pleural mesothelioma. Annals of Cardiothoracic Surgery 2012;1(4):502‐7.
Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Annals of the New York Academy of Sciences 2013;1291:1‐13.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier‐Valette C, Moro‐Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open‐label, phase 3 trial. Lancet 2016;387(10026):1405‐14.
